{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T18:55:58Z","timestamp":1784746558669,"version":"3.55.0"},"reference-count":17,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"unspecified","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Helmholtz Association Initiative and Networking Fund","award":["grant# ZT-I-PF-5-01"],"award-info":[{"award-number":["grant# ZT-I-PF-5-01"]}]},{"name":"German Federal Ministry of Education and Research","award":["BMBF, grant# 031L0210A"],"award-info":[{"award-number":["BMBF, grant# 031L0210A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Ophth"],"accepted":{"date-parts":[[2025,5,6]]},"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Age-related macular degeneration (AMD) remains the leading cause of blindness in developed countries. There are many different intravitreal anti-vascular endothelial growth factor (VEGF) drugs available for the treatment of neovascular AMD (nAMD). Unfortunately, not all patients respond equally well to the drugs, and some show recurrences during treatment. Since 01\/2024, aflibercept 8\u2009mg represents an additional treatment option and contains a four times higher dosage than the already known aflibercept 2\u2009mg.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>To evaluate the real-world efficacy of aflibercept 8\u2009mg in refractory nAMD patients, focusing on changes in key optical coherence tomography biomarkers over a follow-up period of the first four aflibercept 8\u2009mg injections using a deep learning-based semantic segmentation algorithm. Inclusion criteria were: switch to aflibercept 8\u2009mg after insufficient response to aflibercept 2\u2009mg, marked by persistent retinal fluid or inability to extend treatment beyond 6\u2009weeks; completion of at least 3\u2009months (90 days) follow-up under treat-and-extend treatment regime; and no confounding conditions like intraocular infection, uveitis or other retinal diseases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>23 eyes of 21 patients with therapy-resistant nAMD were switched to aflibercept 8\u2009mg. All patients had previously received aflibercept 2\u2009mg, with an average of 30.7 previous anti-VEGF injections. Significant reductions in intraretinal fluid and fibrovascular pigment epithelial detachment at timepoint V3 were observed. The decrease in subretinal fluid and central retinal thickness at V3 was not significant. Treatment intervals extended significantly by 24%, from a baseline average of 34 days to 42 days. Best-corrected visual acuity remained stable throughout the study period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Aflibercept 8\u2009mg demonstrated significant efficacy and durability in reducing nAMD biomarkers and extending intervals in a real-world setting. The use of deep learning for biomarker quantification highlighted its potential for enhancing treatment monitoring and decision-making. Future studies with a larger patient cohort and prospective study setting should explore long-term outcomes and integration of artificial intelligence-driven analysis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjophth-2025-002176","type":"journal-article","created":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T16:20:13Z","timestamp":1748794813000},"page":"e002176","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Deep learning-assisted analysis of biomarker changes after increase of dosing from aflibercept 2 mg to 8 mg in therapy-resistant neovascular age-related macular degeneration"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-9025-259X","authenticated-orcid":false,"given":"Michael","family":"Hafner","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, LMU University Hospital, LMU Munich, Munich, BY, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Asani","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, LMU University Hospital, LMU Munich, Munich, BY, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Eckardt","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, LMU University Hospital, LMU Munich, Munich, BY, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caspar","family":"Liesenhoff","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, LMU University Hospital, LMU Munich, Munich, BY, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Kufner","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, LMU University Hospital, LMU Munich, Munich, BY, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0279-4823","authenticated-orcid":false,"given":"Jakob","family":"Siedlecki","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, LMU University Hospital, LMU Munich, Munich, BY, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0753-2408","authenticated-orcid":false,"given":"Benedikt","family":"Schworm","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, LMU University Hospital, LMU Munich, Munich, BY, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siegfried","family":"Priglinger","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, LMU University Hospital, LMU Munich, Munich, BY, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5357-7469","authenticated-orcid":false,"given":"Johannes Benedikt","family":"Schiefelbein","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, LMU University Hospital, LMU Munich, Munich, BY, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,6,1]]},"reference":[{"key":"2026010721205697000_10.1.e002176.1","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.85.3.261"},{"key":"2026010721205697000_10.1.e002176.2","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1007\/s00417-022-05586-w","article-title":"Macular neovascularization lesion type and vision outcomes in neovascular age-related macular degeneration: post hoc analysis of HARBOR","volume":"260","author":"Freund","year":"2022","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2026010721205697000_10.1.e002176.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054481"},{"key":"2026010721205697000_10.1.e002176.4","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1097\/IAE.0000000000000627","article-title":"TREAT-AND-EXTEND REGIMENS WITH ANTI-VEGF AGENTS IN RETINAL DISEASES: A Literature Review and Consensus Recommendations","volume":"35","author":"Freund","year":"2015","journal-title":"Retina"},{"key":"2026010721205697000_10.1.e002176.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.02.009"},{"key":"2026010721205697000_10.1.e002176.6","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","article-title":"Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials","volume":"399","author":"Heier","year":"2022","journal-title":"The Lancet"},{"key":"2026010721205697000_10.1.e002176.7","unstructured":"New Eylea 8 mg approved in EU . News release. Bayer AG. Available: https:\/\/www.bayer.com\/media\/en-us\/new-eylea-8-mg-approved-in-eu [Accessed 18 Sep 2024]."},{"key":"2026010721205697000_10.1.e002176.8","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1038\/s41433-024-03264-1","article-title":"Evaluation of OCT biomarker changes in treatment-naive neovascular AMD using a deep semantic segmentation algorithm","volume":"38","author":"Asani","year":"2024","journal-title":"Eye (Lond)"},{"key":"2026010721205697000_10.1.e002176.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.11.004"},{"key":"2026010721205697000_10.1.e002176.10","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(89)32814-4"},{"key":"2026010721205697000_10.1.e002176.11","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/jamaophthalmol.2023.2421","article-title":"Effect of High-Dose Intravitreal Aflibercept, 8 mg, in Patients With Neovascular Age-Related Macular Degeneration: The Phase 2 CANDELA Randomized Clinical Trial","volume":"141","author":"Wykoff","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"2026010721205697000_10.1.e002176.12","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0140-6736(24)00063-1","article-title":"Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial","volume":"403","author":"Lanzetta","year":"2024","journal-title":"The Lancet"},{"key":"2026010721205697000_10.1.e002176.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.10.014"},{"key":"2026010721205697000_10.1.e002176.14","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1097\/IAE.0000000000001726","article-title":"High-dose high-frequency aflibercept for recalcitrant neovascular age-related macular degeneration","volume":"38","author":"You","year":"2018","journal-title":"Retina"},{"key":"2026010721205697000_10.1.e002176.15","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1177\/24741264221150345","article-title":"High-Dose Aflibercept for Neovascular AMD and DME in Suboptimal Responders to Standard-Dose Aflibercept","volume":"7","author":"Nielsen","year":"2023","journal-title":"J Vitreoretin Dis"},{"key":"2026010721205697000_10.1.e002176.16","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000037839","article-title":"Switching to the aflibercept (3\u2009mg) therapy for treatment-resistant wet age-related macular degeneration: 1-year outcomes","volume":"103","author":"Feng","year":"2024","journal-title":"Medicine (Baltimore)"},{"key":"2026010721205697000_10.1.e002176.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2018.11.025"}],"container-title":["BMJ Open Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjophth-2025-002176","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T05:21:50Z","timestamp":1767849710000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjophth.bmj.com\/lookup\/doi\/10.1136\/bmjophth-2025-002176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,6,1]]},"published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1136\/bmjophth-2025-002176"],"URL":"https:\/\/doi.org\/10.1136\/bmjophth-2025-002176","relation":{},"ISSN":["2397-3269"],"issn-type":[{"value":"2397-3269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5]]}}}